Bruker Cellular Analysis is looking forward to attending the 8th CAR-TCR Summit, the world’s pre-eminent industry-leading comprehensive forum that unites the global cell therapy community across a variety of cell types. From August 29 – September 1st in Boston, MA, this conference will feature groundbreaking presentations, panel discussions, and poster sessions focused on CAR-T and TCR therapies across all stages of the development pipeline.
Bruker Cellular Analysis will be exhibiting at CAR-TCR in booth #C31 to meet with attendees and discuss how our platforms can uniquely capture aspects of the phenome required to accelerate cell therapies from discovery and bioprocessing to translational and clinical research. Throughout the conference, attendees will have the unique opportunity to interact with Bruker Cellular Analysis’ powerful single-cell systems, the Beacon® optofluidic system and IsoSpark™ system, allowing attendees to visualize the systems’ deep functional profiling capabilities in a streamlined workflow. Attendees are encouraged to stop by to interact with these instruments and see a short demo to learn how this technology can improve their own research programs.
On Wednesday, August 30th, Troy Lionberger, SVP Business Development at Bruker Cellular Analysis will be participating with other industry leaders in a panel discussion titled, “Exploring the Future of Cell Therapy Characterization to Ensure High Quality Products.” The panel will be discussing the following topics:
- What are the current challenges when characterizing your cell therapy candidates and products? How can we solve this issue?
- How can we provide more systematic and unbiased insights to enable deeper characterization?
- What new equipment and methodologies can we utilize?
Using Single-Cell Functional Profiling to Advance Cell Therapies
Bruker Cellular Analysis’ single-cell functional analysis has already been used in a variety of studies to investigate and help to improve CAR-T and TCR therapies. In a 2023 study published in Nature Biotechnology, researchers at St. Jude’s Research Hospital investigated whether improving the strength of CAR binding could yield more effective CAR NK cells. The study set out to investigate how changing CAR-T binding motifs, rather than the target they bind to, affects CAR NK function.
To evaluate this novel approach, they turned to Bruker Cellular Analysis’ IsoCode® Single-Cell Secretome platform and found that the CAR NK cells modified to bind more strongly to solid tumor antigens (CAR.PDZ cells) had higher polyfunctionality and significantly higher PSI compared to control CAR NK cells. The authors used Bruker Cellular Analysis’ single-cell proteomic barcoding technology to demonstrate how their novel modification improved NK cell efficacy and function, which was associated with improved anti-tumor activity.
In another study published recently in Nature Communications, researchers at WUSTL sought to investigate whether CAR-T functionality could be maintained with their novel long-acting IL-7-mediated expansion method. Bruker Cellular Analysis’ IsoCode® Single-Cell Secretome platform revealed that long-acting IL-7-mediated expansion resulted in no loss of CAR-T functionality, defined by Polyfunctional strength index® (PSI®), Bruker Cellular Analysis’ biomarker for immune cell potency, and that polyfunctionality was driven by effector molecules. In mouse models, the expanded CAR-T cells showed improved proliferation, persistence and cytotoxicity resulting in long-term tumor-free survival.
We’d love to have the opportunity to discuss your cell therapy research needs with you at CAR-TCR! Visit us at Booth #C31 to interact with our game-changing platforms and learn more about how Bruker Cellular Analysis’ capabilities can help you advance your research.